Please see dial-in details for the Novo Nordisk’s R&D investor
conference call in connection with ADA.
The presentation will be
followed by a Q&A session.
Hosted by Karsten Munk Knudsen, EVP & CFO
Presenting
Martin Holst Lange, EVP of Development
Marcus Schindler, EVP of
Research and Early Development
28 June 2021
16.00 CEST
15.00 BST
10.00 EDT
The call is expected to last approximately 75 minutes.
Dial-in details:
Denmark:....................... +45 35445577
UK/International:.......... +44 3333000804
USA:………..…..........…….+1 6319131422
Confirmation Code:...... 50002476#
Conference call webcast (05 May 2021, 13:00 CET)
Conference call audio link (05 May 2021, 13:00 CET)
London webcast (06 May 2021, 13:00 CET)
London earnings presentation audio link (06 May 2021, 13:00 CET)
| 1 July - 5 August 2021 | Silent period |
| 5 August 2021 | Q2 2021 financial results release |
| 18 August 2021 | Interim dividend payment for B shares |
| 25 August 2021 | Interim dividend payment for ADRs |
| 1 October - 3 November 2021 | Silent period |
| 3 November 2021 | Q3 2021 financial results release |
| 1 January - 2 February 2022 | Silent period |
| 2 February 2022 | Q4 2021 financial results release |
07 June: Approval of Wegovy™ in the US
21 May: International Operations call
- Annual report 2020 (UK)
-
Company
announcement
- Novo Nordisk CEO reflects on the full year results (video)
- Investor presentation
-
Conference call webcast (03 February 2021,
13:00 CET)
- Conference call audio link (03 February 2021, 13:00 CET)
- London webcast (05 February 2021, 12:00 CET)
- London earnings presentation audio link (05 February 2021, 12:00 CET)
- Financial workbook
- Company Announcement
- Investor presentation
- Conference call webcast (30 Oct 2020, 13:00 CET)
- Conference call audio link (30 Oct 2020, 13:00 CET)
- London webcast (2 Nov 2020, 13:00 CET)
- London earnings presentation audio link (2 Nov 2020, 13:00 CET)
- Financial workbook
- Company announcement
- Investor presentation
- Conference call webcast (6 Aug 2020, 13:00 CET)
- Conference call audio link (6 Aug 2020, 13:00 CET)
- London webcast (7 Aug 2020, 13:00 CET)
- London earnings presentation audio link (7 Aug 2020, 13:00 CET)
- Financial workbook
- Company announcement
- Investor presentation
- Conference call
webcast (6 May 2020, 13:00 CET)
- Conference call audio link (6 May 2020, 13:00 CET)
- London webcast (7 May
2020, 13:00 CET)
- London earnings presentation audio link (7 May 2020, 13:00 CET)
- Financial workbook
16 December: Decision to enter phase 3 development in Alzheimer’s disease and GLP-1 R&D strategy update
30 November: ESG conference call
- Presentation (webcast)
-
ESG presentation (pdf)
- Introduction
- Circular for Zero followed by Q&A
- Defeat Diabetes and Sustainable Workplace followed by Q&A
- Governance structure followed by
Q&A
9 October: Novo Nordisk raises sales and operating profit outlook
for 2020
19 June: R&D investor presentation
26 March: Annual General Meeting
- Conference call webcast (5 February, 13:00 CET)
- London webcast (6 February, 14:15 CET)
- Conference call webcast (1 November, 13:00 CEST)
- London webcast (4 November, 14:15 CEST)
- Annual General meeting (webcast)
- Generalforsamling (webcast)
- Aktionærmøde (webcast)
- Capital Markets Day (webcast)
- Annual General meeting (webcast)
- Generalforsamling (webcast)
- Aktionærmøde (webcast)
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}
